CAW
PTCT icon

Cornerstone Advisors (Washington)’s PTC Therapeutics PTCT Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-50
Closed -$1K – 931
2017
Q2 		$1K Buy
+50
New +$674 ﹤0.01% 878
2017
Q1 		– Sell
-50
Closed -$1K – 945
2016
Q4 		$1K Hold
50
– – ﹤0.01% 906
2016
Q3 		$1K Sell
50
-50
-50% -$406 ﹤0.01% 877
2016
Q2 		$1K Hold
100
– – ﹤0.01% 829
2016
Q1 		$1K Hold
100
– – ﹤0.01% 825
2015
Q4 		$3K Buy
100
+50
+100% +$1.47K ﹤0.01% 669
2015
Q3 		$1K Buy
+50
New +$2.14K ﹤0.01% 834

Other funds holding PTCT

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Cornerstone Advisors (Washington)'s PTCT Position: Q3 2017 in Review

Cornerstone Advisors (Washington) sold out of PTC Therapeutics (PTCT) in Q3 2017, closing a stake of 50 shares — an estimated $1K sold.

Cornerstone Advisors (Washington) first reported a position in PTCT in Q3 2015 and held it in 7 quarters. The position peaked at $3K in Q4 2015. 129 funds tracked by Wall St. Rank hold PTCT as of Q3 2017.

  • Cornerstone Advisors (Washington) reported no remaining PTC Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Cornerstone Advisors (Washington) sold 50 PTC Therapeutics shares in Q3 2017, an estimated $1K.
  • Cornerstone Advisors (Washington) first reported a position in PTC Therapeutics in Q3 2015 and held it in 7 quarters.
  • Cornerstone Advisors (Washington)'s PTC Therapeutics position peaked at $3K in Q4 2015.
  • 129 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2017.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q3 2017, filed 25 Oct 2017.